Pfizer Plans To Restart Tanezumab Trials In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
While questions about the company’s internal reorganization dominated its second-quarter earnings call, Pfizer management also provided some clinical and pipeline updates. Pfizer said the partial clinical hold on its anti-nerve growth factor tanezumab has been lifted and it is preparing to begin Phase III clinical trials in 2014.
You may also be interested in...
Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms
With galcanezumab for cluster headaches and migraine and tanezumab for osteoarthritis, lower back pain and cancer pain, Lilly soon could have an up-and-running pain franchise bolstering its long-term, internal R&D strategy.
Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III
Pfizer and Lilly plan to resume Phase III testing of their nerve growth factor inhibitor after FDA lifted a partial hold on tanezumab. But J&J is also poised to run new Phase III studies with fulranumab.
Lilly’s Glyxambi Is First SGLT2/DPP-4 Combo Product For Diabetes
Glyxambi is the latest in a series of new diabetes drugs for Eli Lilly, following on the heels of Jardiance and Trulicity. The company highlighted new drugs and its pipeline during its year-end financial call.